Skokie, IL — The ISSCR is bringing together successful biotech CEOs who have transformed scientific breakthroughs into thriving businesses that are improving human health into one program 7-8 January 2021.

VISION2030 comes at a pivotal moment in regenerative medicine and stem cell science as discovery, translation, and investment intersect.

Thursday, 7 January

12:00 to 4:00 PM EST (view your time zone)

STEMCELL Technologies Executive Interview

Allen Eaves, Scientific Founder l Chief Executive Officer, STEMCELL Technologies, Canada

Interviewed by ISSCR Board Member Valentina Greco, Yale University School of Medicine, USA

STEMCELL Technologies’ mission is to advance the pursuit of scientific knowledge by supplying high quality, innovative reagents, tools, and services that enable life science research.

Surrozen Executive Interview

Craig Parker, Chief Executive Officer, Surrozen, USA

Claudia Janda, Princes Máxima Centrum, Netherlands l Surrozen Founder

Interviewed by ISSCR Past President Hans C. Clevers, Hubrecht Institute, Netherlands l Surrozen Founder

Surrozen is pioneering a new class of targeted regenerative antibodies to repair a broad range of tissues and restore organs damaged by serious disease.

ElevateBio Executive Interview

Mitchell Finer, Scientific Founder and Chief Executive Officer, ElevateBio, USA

Melissa Carpenter, Chief Scientific Officer, ElevateBio, USA

Interviewed by ISSCR Board Member Martin Pera, The Jackson Laboratories, USA l Stem Cell Reports Editor-in-Chief

ElevateBio is accelerating the rate of innovation in cell and gene therapy with a disruptive capital-efficient model.


Andrew Gaffney, Associate Director, iPSC and Differentiated Cells

Sponsored content

BlueRock Therapeutics Executive Interview

Emile Nuwaysir, President and Chief Executive Officer, BlueRock Therapeutics, USA

Lorenz Studer, Founding Scientist, BlueRock Therapeutics l Sloan Kettering Institute for Cancer Research, USA

Viviane Tabar, Founding Scientist, BlueRock Therapeutics l Memorial Sloan Kettering Center, USA

Interviewed by ISSCR Board Member Arnold Kriegstein, University of California, San Francisco, USA

BlueRock Therapeutics is advancing their novel cell+gene platform to develop, manufacture, and deliver an entirely new generation of authentic and engineered cell therapies across three therapeutic areas: neurology, cardiology, and immunology.

Vertex Pharmaceutical Executive Interview

Jeffrey Leiden, Executive Chairman, Vertex Pharmaceutical, USA

Bastiano Sanna, Executive Vice President, Chief of Cell & Genetic Therapies & VCGT Site Head, Vertex Pharmaceuticals, USA

Interviewed by ISSCR Past President Douglas A. Melton, Scientific Founder, Semma Therapeutics, now Vertex Pharmaceutical l Harvard University, USA

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.

Tenaya Therapeutics Executive Interview

Faraz Ali, Chief Executive Officer, Tenaya Therapeutics, USA

Deepak Srivastava, Scientific Founder, Tenaya Therapeutics l Gladstone Institute/UCSF, USA l ISSCR Immediate Past President

Interviewed by ISSCR Board Member Charles E. Murry, Institute for Stem Cell and Regenerative Medicine, University of Washington/Sana Biotechnologies, USA

Tenaya Therapeutics is a company with a mission to discover, develop, and deliver curative therapies that target the underlying causes of heart disease.

Fate Therapeutics Executive Interview

Scott Wolchko, President and Chief Executive Officer, Fate Therapeutics, USA

Leonard I. Zon, Scientific Founder, Fate Therapeutics l Boston Children’s Hospital, USA l ISSCR Founder

Interviewed by ISSCR Board Member Takanori Takebe, Cincinnati Children’s Hospital Medical Center, USA/Tokyo Medical and Dental University and Yokohama City University, Japan

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders.


Thought Leaders—Pivoting to the Future

Margaret A. Hamburg, WHO Expert Advisory Group On Developing Global Standards for Governance and Oversight of Human Genome Editing and Global Standards for Governance and Oversight of Human Genome Editing l Former FDA Commissioner, USA

Rajiv Kaul, Fidelity Select Biotechnology, USA

Andrew Plump, Takeda Pharmaceutical Company Limited, USA

Jim Tananbaum, Foresite Capital, USA

Interviewed by ISSCR Immediate Past President Deepak Srivastava, Gladstone Institute/UCSF, USA

Concluding Remarks

Christine Mummery, ISSCR President / Leiden University Medical Center, Netherlands

Friday, 8 January

12:00 NOON-1:30 PM EST (view your time zone)

Sponsored Industry Career Talks

Join us as participating companies discuss how the future of the stem cell field will shape the future of our careers — new opportunities, paths, and challenges. Attendees will hear from talent recruitment leaders and scientists who will discuss the transition from academia to industry, how to make it, and what to expect.


Keith Alm, ISSCR Chief Operating Officer, USA

Julia Tischler, ISSCR Membership Committee l École Polytechnique Fédérale de Lausanne, EPFL, Switzerland (invited)

STEMCELL Technologies, Inc.

Christine Genge, Manager, Recruitment

Nina Quiskamp, Scientist

Question and Answer

BlueRock Therapeutics

Timsi Rao, Genome Sciences, Immunology

Stephany Sakharny, Senior Human Resources Manager

Question and Answer


Cherylene Plewa, Vice President, Cellular Engineering

Austin Thiel, Director Stem Cell Biology

Question and Answer

Concluding Remarks

Keith Alm, ISSCR Chief Operating Officer, USA


Media are welcome to attend. Contact Kym Kilbourne at for access.

About the International Society for Stem Cell Research

With nearly 4,000 members from more than 60 countries, the International Society for Stem Cell Research is the preeminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic. The ISSCR mission is to promote excellence in stem cell science and applications to human health. Additional information about stem cell science is available at A Closer Look at Stem Cells, an initiative of the Society to inform the public about stem cell research and its potential to improve human health.